| Literature DB >> 33225895 |
Zhen Zhang1,2, Yi-Shuang Xiao3, Ru Shen4, Hong-Chao Jiang1, Li Tan4, Ren-Qiu Li4, Xiao-Hong Yang4, Huai-Yu Gu5, Wen-Ji He6, Jing Ma7,8.
Abstract
BACKGROUND: Retinoblastoma is a rare intraocular malignancy and typically initiated by inactivating biallelic mutations of RB1 gene. Each year, ~ 8000 children worldwide are diagnosed for retinoblastoma. In high-income countries, patient survival is over 95% while low-income countries is ~ 30%.If disease is diagnosed early and treated in centers specializing in retinoblastoma, the survival might exceed 95% and many eyes could be safely treated and support a lifetime of good vision. In China, approximate 1100 newly diagnosed cases are expected annually and 28 hospitals covering 25 provinces established centers classified by expertise and resources for better treatment options and follow-up. Comparing with other province of eastern China, Yunnan province is remote geographically. This might result that healthcare staff have low awareness of the role of genetic testing in management and screening in families.Entities:
Keywords: Genetic forms; Mutations; Retinoblastoma; Targeted next generation sequencing
Mesh:
Substances:
Year: 2020 PMID: 33225895 PMCID: PMC7682003 DOI: 10.1186/s12881-020-01150-7
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Fig. 1Pedigree of families with RB. Unaffected subjects are denoted as blank while affected subjects are represented with darkened symbols. The arrow indicates the proband. a .Pedigree of the family 1; b. Pedigree of the family 2; c. Pedigree of the family 3; d. Pedigree of the family 4;. e. Pedigree of the family 5; f. Pedigree of the family 6; g. Pedigree of the family 7; h. Pedigree of the family 8; i. Pedigree of the family 9
Clinical features of patients with RB
| Patient | Sex | Minority Nationalities | Age (Months) | Onset Age (Months) | Fundus Appearance | ||
|---|---|---|---|---|---|---|---|
| LE | RE | LE | RE | ||||
| 1 | M | Dai | 12 | 6 | 6 | RB | RB |
| 2 | M | Hani | 106 | 14 a | 17 | – | RB |
| 3 | F | Bai | 12 | 9 | – | RB | – |
| 4 | F | Han | 18 | 13 | 13 | RB | RB |
| 5 | M | Hui | 28 | 26 | 26 | RB | RB |
| 6 | M | Yi | 11 | 6 | – | RB | – |
| 7 | M | Hani | 60 | 54 | – | RB | – |
| 8 | M | Han | 6 | 5 | 5 | RB | RB |
| 9 | M | Han | 10 | 3 | 3 | RB | RB |
Abbreviations: M Male, LE Left eye, RE Right eye, Retinoblastoma (RB);The children of these families exhibited similar clinical features of RB. Ophthalmic examinations showed that the child in these families are affected by RB. a Removed at 15 months
Variants identified by NGS in blood samples of RB chidren
| No. | Locations on thechromosomes | Exon | Mutation | Pathogenicanalysis | Allele | Protein | Cosegregation infamily | |
|---|---|---|---|---|---|---|---|---|
| 1 | chr13–48,942,673-48,942,675 | 11 | c.1061_1062del | novel | pathogenic | het | p.R355Nfs*6 | De novo |
| 2 | chr13–49,030,485 | 19 | c.1960 G > C | known | Likely pathogenic | het | p.V654L | De novo |
| 3 | chr13–49,039,158 | 22 | c.2236 G > T | novel | pathogenic | het | p.E746X | Heterozygous mother |
| 4 | chr13–49,047,526-49,047,530 | 24 | c.2520 + 1_2520 + 4delGTGA | novel | pathogenic | het | splicing | De novo |
| 5 | chr13–48,955,538 | 17 | c.1654 C > T | known | Pathogenic | het | p.R552X | De novo |
| 6 | chr13–49,027,168 | 18 | c.1735 C > T | known | pathogenic | het | p.R579X | De novo |
| 7 | chr13–48,881,547 | 2 | c.264 + 5G > A | novel | pathogenic | het | splicing | De novo |
| 8 | chr13–48,942,685 | 11 | c.1072C > T | known | pathogenic | het | p.R358X | De novo |
| 9 | chr13–48,923,160 | 6 | c.607 + 1G > A | known | pathogenic | het | splicing | De novo |
*means termination
Fig. 2The variants of the probands. Arrows denote the mutations (the proband). Mutations of retinoblastoma identified by Sanger Sequencing in family 1, 4, 7. a The mutation of the family1; b The mutation of the family 4; c The mutation of the family 7
Fig. 3The variants of the probands in family 3